BEPO® Technologie

Injection
à action prolongée

Play video

Notre technologie BEPO® permet de développer des traitements injectables à action prolongée

Notre technologie brevetée BEPO® permet de contrôler et de garantir la délivrance régulière à dose thérapeutique optimale d’un médicament pendant plusieurs jours, semaines ou mois. Lors de l’injection, la technologie BEPO® permet de former un dépôt de polymères de quelques millimètres sous la peau pour une action systémique, ou localement pour une action ciblée. Le dépôt diffuse le principe actif en se résorbant pendant la durée souhaitée à l’image d’une mini pompe qui serait injectable et bio-résorbable.

Dans de nombreuses indications

Une fois un besoin identifié, le potentiel du produit validé et sa faisabilité technique évaluée positivement, les équipes de MedinCell créent un prototype respectant les spécifications ciblées, notamment la durée d’action et la dose de principe actif devant être diffusée de manière régulière. Pour chaque produit, une nouvelle association de polymères est créée, ce qui rend chaque formulation unique et exclusive.

BEPO® Technologie

BEPO ®
en détails

BEPO® est composé d’une solution de copolymères diblock (DB) et triblock (TB) contenant des blocs hydrophiles et hydrosolubles (polyéthylène glycol – PEG) liés à des blocs hydrophobes et amorphes (Poly(D,L-acide lactique) – PLA) qui précipitent en formant un dépôt lorsqu’ils sont exposés à un environnement aqueux. L’API est piégé dans la matrice polymérique et est ensuite libéré par diffusion suite à la dégradation du polymère. L’hygrométrie et par conséquent la cinétique de libération de l’API des dépôts peuvent être affinées en ajustant l’hydrophilie de du DB, du TB et leur rapport relatif.

PEG

• Également connu sous le nom d’oxyde de polyéthylène (PEO)
• Disponible dans le commerce sur une large gamme de MW
• Hydrophile, soluble dans l’eau

PLA

• Poly (D,L-acide lactique) ou poly (D,L-lactide)
• Préparé par polymérisation (ROP) de monomère cyclique (D,L)-lactide
• Amorphe, hydrophobe
• Macromolécule biodégradable (par hydrolyse)

BEPO® copolymères

Diblock Copolymères (DB)

Triblock Copolymères (TB)

BEPO® Technologie

Scientific & Technical
Advisory Board

Prof. dr. ir. Tina Vermonden

Prof. dr. ir. Tina Vermonden Utrecht University, The Netherlands
Biomaterials for Regenerative Medicine and Drug Delivery

After obtaining a PhD in Organic Chemistry at Wageningen University, Tina Vermonden moved to Utrecht University in 2005 to join the Pharmaceutics division as a postdoctoral researcher. Since then, her research has focused on biomaterials science, which is a multidisciplinary field of research encompassing elements of medicine, biology, chemistry, and materials science. In 2020, she was appointed as full professor. Tina’s group focusses mainly on the development of polymeric materials that are suitable as either protein or drug delivery matrices or as scaffolds for regenerative medicine. Important parameters are biocompatibility, degradability and stability in time under physiological conditions.

Prof. Ph.D. Jesper Østergaard

Jesper Østergaard is Professor of Pharmaceutical Physical Chemistry at Department of Pharmacy, University of Copenhagen. Dr. Østergaard is a pharmacist (1999) and obtained his Ph.D. in pharmaceutics working on molecular interaction studies and prodrug design in Copenhagen in 2003. Subsequently, he became Assistant and Associate Professor (2003, 2006) and since 2019 Professor at Department of Pharmacy. Main research interests include development of methods for physical-chemical characterization of drug substances and delivery systems, drug transport, dissolution and release. Focus is on the development of analytical methods for in vitro dissolution and release testing (including UV imaging), and on molecular interactions and stability assessment related to profiling of drug substances and delivery systems using capillary-based methods such as capillary electrophoresis (CE) and Taylor dispersion analysis/Flow induced dispersion analysis (TDA/FIDA). He has published >150 scientific papers. Dr. Østergaard is the co-founder of two spin-outs from University of Copenhagen.

Prof. PhD Juergen Siepmann

Juergen Siepmann studied pharmacy and did his Ph.D. at the Freie Universitaet Berlin, Germany. Since 2004 he is Professor of Pharmaceutical Technology at the University of Lille, France.

His research focuses on controlled drug delivery systems, in particular on the elucidation of the underlying mass transport phenomena, mathematical modeling and the optimization of the devices. He is heading the Inserm (French National Institute of Health and Medical Research) research group “Advanced Drug Delivery systems”, counting about 50 members.

Since 2010 he serves as president of the APGI (https://www.apgi.org), and since 2016 as Editor-in-Chief of the “International Journal of Pharmaceutics” (https://www.journals.elsevier.com/international-journal-of-pharmaceutics).

Prof. PhD Sébastien Lecommandoux

Sébastien Lecommandoux received in 1996 his PhD in Physical Chemistry from the University of Bordeaux. After a postdoctoral experience at the University of Illinois (UIUC, USA) in the group of Prof. Samuel I. Stupp, he started his academic career at the Laboratoire de Chimie des Polymères Organiques as Associate Professor in 1998 and was promoted to Full Professor at Bordeaux INP in 2005. He is currently Director of the Laboratoire de Chimie des Polymères Organiques (LCPO-CNRS) and is leading the group “Polymers Self-Assembly and Life Sciences”. His research interests include polypeptide and polysaccharide-based block copolymers self-assembly, the design of polymersomes for drug-delivery and theranostic, as well as biomimetic approaches toward design of synthetic viruses and artificial cells. He has published more than 180 papers in international journal with more than 15,000 citations (h-index 61), 7 book chapters and 10 patents (2 being licenced, 1 start-up created). Sébastien Lecommandoux is recipient of the CNRS bronze medal (2004), Institut Universitaire de France Junior Chair (IUF 2007), Fellow of the Royal Society of Chemistry RSC (2017), Seqens Award of the French Academy of Science (2019), Member of the Academia Europaea (2020). He is Editor-in-Chief of Biomacromolecules (ACS) since 2020 after being Associate Editor since 2013. He is also in the Editorial Advisory Board of several international journals, including Bioconjugate Chemistry (ACS), Polymers (MDPI), Polymer Chemistry (RSC) and Biomaterials Science (RSC).

Dr CNRS Emérite Michel Vert

Graduation at the University of Paris in 1963 and DSc doctorate at the University of Rouen in France in 1969. Junior scientist at the National Centre for Scientific Research (CNRS) in 1965. Senior scientist at CNRS in 1971. Founder and Head of the Laboratory of Macromolecular Substances at the National Institute for Applied Sciences at Rouen in 1981. CNRS Research Director (Research Professor) in 1984. Join the University of Montpellier 1 in 1991 to create the Research Centre for Artificial Biopolymers, CNRS Research Mixed Unit 5473. Director of this laboratory that made researches at the interfaces between chemistry, polymeric biomaterials, biology and health until 2007. Emeritus CNRS Research Director since then. Main fields of interest: – optically active polymers, – multifunctional polyelectrolytes, -polymers of therapeutic interest, – macromolecular drugs and prodrugs, -degradable and bioresorbable polymers, – smart polymeric systems. Author or co-author of more than 400 major articles and book chapters, and of 28 patents, several of them licensed to companies. Co-founder of MedinCell and Arterial Remodelling Technologies Companies. Ex-Editor of the Journal of Biomaterials Science: Polymer Edition. Member of the editorial board of several scientific journals. Member of the IUPAC Sub-Committee for Polymer Terminology. Awarded CNRS Silver Medal in 1989, the “Jungfleish” Grand Prix of the French Academy of Sciences in 2001, European Grand Prix of Innovation for the Environment Monaco in 2005 and Grand Prix Georges Winter of the European Society for Biomaterials in 2005.

BEPO® Technologie

Publications
& Conférences

avril 17, 2023

Poster pour le European Congress of Clinical Microbiology and Infectious Diseases 2023

mars 25, 2023

Evaluating the in vivo stability of water-soluble PEG-PLA copolymers using FRET imaging

février 14, 2023

Proof-of-concept study for a long-acting formulation of ivermectin injected in cattle as a complementary malaria vector control tool

juillet 28, 2022

Long-acting injectable formulation technologies: Challenges and opportunities for the delivery of fragile molecules

décembre 12, 2021

Intra-articular delivery of full-length antibodies through the use of an in situ forming depot

août 26, 2021

Evaluation of Loco-Regional Skin Toxicity Induced by an In Situ Forming Depot after a Single Subcutaneous Injection at Different Volumes and Flow Rates in Göttingen Minipigs

août 10, 2021

Impact of octreotide counterion nature on the long-term stability and release kinetics from an in situ forming depot technology

juin 04, 2021

Approaches for Systemic Delivery of Dystrophin Antisense Peptide Nucleic Acid in the mdx Mouse Model

avril 22, 2021

Poly(ethylene glycol)-b-poly(1,3-trimethylene carbonate) Copolymers for the Formulation of In Situ Forming Depot Long-Acting Injectables

mars 06, 2021

Poly(ethylene glycol)-b-poly(1,3-trimethylene carbonate) Amphiphilic Copolymers for Long-Acting Injectables: Synthesis, Non-Acylating Performance and In Vivo Degradation

mai 18, 2020

Effects of an injectable long-acting formulation of ivermectin on Onchocerca ochengi in zebu cattle

mars 10, 2020

BEPO®: Bioresorbable diblock mPEG-PDLLA and triblock PDLLA-PEG- PDLLA based in situ forming depots with flexible drug delivery kinetics modulation

septembre 20, 2018

Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation

Session en français

Mardi 19 décembre, 18h30 : Présentation des résultats du premier semestre de l'année fiscale 2023-24

English session

Tuesday, December 19, 6:30 pm: Half-year earnings call (April 1st - September 30th)

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
Ce champ n’est utilisé qu’à des fins de validation et devrait rester inchangé.

CONTACT

  • Ce champ n’est utilisé qu’à des fins de validation et devrait rester inchangé.